Danaher Corporation (BVMF:DHER34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 633.16B -21.7% |
| Revenue (ttm) | 129.86B +4.0% |
| Net Income | 19.33B -2.0% |
| EPS | 27.14 +0.4% |
| Shares Out | n/a |
| PE Ratio | 32.75 |
| Forward PE | 20.70 |
| Dividend | 0.17 (0.55%) |
| Ex-Dividend Date | Mar 26, 2026 |
| Volume | 1,518 |
| Average Volume | 1,322 |
| Open | 31.83 |
| Previous Close | 31.93 |
| Day's Range | 31.60 - 31.83 |
| 52-Week Range | 30.95 - 46.06 |
| Beta | 0.99 |
| RSI | 31.86 |
| Earnings Date | Apr 21, 2026 |
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufact... [Read more]
Financial Performance
In 2025, Danaher's revenue was $24.57 billion, an increase of 2.90% compared to the previous year's $23.88 billion. Earnings were $3.61 billion, a decrease of -7.31%.
Financial numbers in USD Financial StatementsNews
Danaher reaches $172.5 million settlement with shareholders over post-pandemic outlook
Danaher reached a $172.5 million settlement with shareholders who accused the diagnostics and life-sciences company of defrauding them by overstating demand for its equipment as the worst of the COV...
Danaher Announces Pricing of Euro-Denominated Senior Notes Offering
WASHINGTON, April 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today that it has priced an offering of the following euro-denominated senior notes (the "Offering"): €...
Danaher Q1 Earnings Beat Estimates, But Revenue Miss, Weak Diagnostics Weigh On Stock
Danaher Corp (NYSE:DHR) on Tuesday reported first-quarter 2026 sales of $5.95 billion, up 3.5% year-over-year, but under the consensus of $5.99 billion. Core revenue increased 0.5% year-over-year.
Danaher Earnings Call Transcript: Q1 2026
Q1 2026 saw strong execution, with core revenue up 0.5% and adjusted EPS up 9.5% year-over-year. Bioprocessing and life sciences offset respiratory headwinds, and the Masimo acquisition is expected to be accretive. Full-year guidance was raised for adjusted EPS.
Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains
Danaher boosted the upper end of its full-year earnings guidance, following a first-quarter beat fueled by double-digit momentum in its Biotechnology and Life Sciences segments.
Danaher beats first-quarter profit estimates on strong bioprocessing demand
Life sciences firm Danaher topped first-quarter profit expectations on Tuesday, fueled by strong demand for its bioprocessing tools used in drug manufacturing, lifting shares 2% in premarket trading.
Danaher Reports First Quarter 2026 Results
WASHINGTON, April 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the first quarter 2026. All results in this release reflect only continuing operations and perio...
Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection Results in Approximately 20 Minutes
Modeling Shows Adoption of New Access MeMed BV Assay Could Cut up to €80M in Avoidable Costs across European Health Systems through Fewer Unnecessary Admissions and Testing BREA, Calif., April 13, 20...
Did Danaher Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Danaher Schedules First Quarter 2026 Earnings Conference Call
WASHINGTON, March 20, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2026 on Tuesday, April 21, 2026 b...
Danaher Transcript: TD Cowen 46th Annual Health Care Conference
Management expects 3%-6% growth in 2026, driven by bioprocessing, life sciences recovery, and diagnostics stabilization. The Masimo acquisition is set to deliver significant synergies and long-term returns, while reshoring and innovation in diagnostics and bioprocessing support sustained growth.
Danaher Announces Quarterly Dividend
WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common st...
Danaher to Present at TD Cowen Health Care Conference
WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conferenc...
Danaher to buy Masimo for $9.9 billion
Danaher will acquire pulse oximeter maker Masimo for $9.9 billion, the company said on Tuesday, as the contract research firm looks to bulk up its diagnostics portfolio.
Masimo to be Acquired by Danaher for $180.00 Per Share
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Dan...
Danaher To Acquire Masimo Corporation
WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo ...
Danaher Strikes $10 Billion Deal for Masimo
The medical-device maker is expected to operate as a stand-alone company within Danaher's Diagnostics segment.
Danaher closes in on nearly $10 billion deal for Masimo, FT reports
US healthcare manufacturer Danaher is closing in a nearly $10 billion deal to acquire medical technology company Masimo , the Financial Times reported on Monday, citing people familiar with the matter...
Halper Sadeh LLC Encourages Danaher Corporation Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Shareholders should contact the firm immediately as there may be limited time to enforce your righ...
Danaher Expects Gradual Improvement In End-Market Conditions
Danaher Corp (NYSE: DHR) on Wednesday reported fourth-quarter 2025 sales of $6.84 billion, up 4.5% year-over-year, beating the consensus of $6.81 billion.
Danaher Earnings Call Transcript: Q4 2025
Strong Q4 and full-year 2025 results featured robust bioprocessing growth, margin expansion, and record free cash flow. 2026 guidance calls for 3%-6% core revenue growth and $8.35-$8.50 EPS, with continued innovation and improving end markets expected to drive performance.
Danaher forecasts 2026 profit in line with estimates on pharma spending recovery
Life sciences firm Danaher Corp forecast annual profit largely in line with Wall Street estimates on Wednesday and beat fourth-quarter profit and revenue expectations, as improving conditions in the p...
Danaher Reports Fourth Quarter and Full Year 2025 Results
WASHINGTON, Jan. 28, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2025. All results in this release reflect only c...
Danaher Transcript: 44th Annual J.P. Morgan Healthcare Conference
Fourth quarter 2025 results are expected to surpass expectations, driven by strong bioprocessing and diagnostics performance. Secular growth drivers, innovation, and a robust M&A strategy position the business for 3%–6% core revenue growth and high single-digit EPS growth in 2026.
Danaher CEO to Comment on Financial Performance
WASHINGTON, Jan. 12, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Compan...